Press Releases

Press Releases 2019

  • LMNL presents new preclinical data on PBI-4050 and its effect on angio-proliferative pulmonary arterial hypertension

    LMNL presents new preclinical data on PBI-4050 and its effect on angio-proliferative pulmonary arterial hypertension

    LMNL to present two scientific posters with new preclinical data for PBI-4050 and the treatment of pulmonary arterial hypertension (“PAH”) at the American Heart Association conference.

    Read Article
  • Liminal BioSciences to present at the Jefferies 2019 London healthcare conference

    Liminal BioSciences to present at the Jefferies 2019 London healthcare conference

    Members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 18:00 GMT on Wednesday, November 20, 2019 in London, UK.

    Read Article
  • Liminal BioSciences announces effectiveness of registration statement on form F-10 and filing of prospectus supplement

    Liminal BioSciences announces effectiveness of registration statement on form F-10 and filing of prospectus supplement

    LMNL announced today that its registration statement on Form F-10 (the “Registration Statement”), which was filed with the United States Securities and Exchange Commission (the “SEC”) on November 12

    Read Article
  • Liminal BioSciences to present at Stifel healthcare conference

    Liminal BioSciences to present at Stifel healthcare conference

    LMNL management team will provide a business overview and update at the Stifel Healthcare Conference at 14:25 ET on Tuesday, November 19, 2019 in New York, USA.

    Read Article
  • Liminal BioSciences to commence trading common shares on NASDAQ

    Liminal BioSciences to commence trading common shares on NASDAQ

    Trading is expected to commence on NASDAQ on Monday, November 18, 2019, under the ticker symbol ‘LMNL’.

    Read Article
  • Liminal BioSciences announces key appointment to its leadership team

    Liminal BioSciences announces key appointment to its leadership team

    LMNL announced today the addition of Moira Daniels as the new Head of Regulatory Affairs and Quality Assurance, to its senior leadership team.

    Read Article
  • Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547

    Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547

    Read Article
  • Liminal BioSciences reports its 2019 third quarter financial results and business highlights

    Liminal BioSciences reports its 2019 third quarter financial results and business highlights

    Read Article
  • Liminal BioSciences to report Q3 2019 results and hold conference call

    Liminal BioSciences to report Q3 2019 results and hold conference call

    Read Article
  • Liminal BioSciences presents new preclinical data at ASN kidney week 2019

    Liminal BioSciences presents new preclinical data at ASN kidney week 2019

    LMNL collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology’s

    Read Article
  • Liminal BioSciences to divest bioseparations division to KKR

    Liminal BioSciences to divest bioseparations division to KKR

    LMNL announced today the signature of a binding share purchase agreement for the divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd

    Read Article
  • Liminal BioSciences announces upcoming presentations with new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

    Liminal BioSciences announces upcoming presentations with new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

    Liminal BioSciences announces upcoming presentations new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting

    Read Article
  • Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

    Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019

    Liminal Bio anannounced the presentation of three abstracts related to the Company’s pre-clinical development activities for the treatment of liver diseases at the The Liver Meeting 2019 of the AASLD

    Read Article
  • Liminal BioSciences announces upcoming presentations at ASN kidney week 2019

    Liminal BioSciences announces upcoming presentations at ASN kidney week 2019

    Liminal BioSciences and its’ collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at ASN Kidney Week.

    Read Article
  • Liminal BioSciences to present at H.C. Wainwright & Co. 3rd annual NASH investor conference

    Liminal BioSciences to present at H.C. Wainwright & Co. 3rd annual NASH investor conference

    Liminal BioSciences announced today, that members of the management team will provide a presentation on PBI-4547 as a potential treatment for NASH

    Read Article
  • Prometic shareholders approve name change to Liminal BioSciences Inc.

    Prometic shareholders approve name change to Liminal BioSciences Inc.

    Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc.

    Read Article
  • Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547

    PBI-4547 is a novel, orally active immune-metabolic agent which displays antidiabetic, antihyperlipidemic, anti-inflammatory and anti-fibrotic activity as shown in multiple animal models.

    Read Article
  • Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

    Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference

    Members of the management team will provide a business overview and update at the H.C. Wainwright & Co. 21st Annual Global Investment Conference at 11:15 EDT on Tuesday, September 10, 2019 in New York

    Read Article
  • Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.

    Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.

    Prometic announced today its intention to change its name as part of a global rebrand in support of its new vision and values.

    Read Article
  • Prometic reports financial results for second quarter 2019

    Prometic reports financial results for second quarter 2019

    Prometic today announced financial results for its fiscal 2019 second quarter ended June 30th 2019.

    Read Article
  • loading
    Loading More...